Abstract
Bone metastasis is frequently seen in NSCLC (non small-cell cancer )and have got poor prognosis. Bone is a hematopoietic organ and actively regulates our immune system. Nivolumab is a fully human IgG4 PD-1 ICI (immune checkpoint inhibitor) antibody, which disrupts PD-1 mediated signaling and restores antitumor immunity. We have studied the clinical outcome of Nivolumab monotherapy in NSCLC patients with bone metastasis.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call